Identifying RNA biomarkers in patients with acute coronary syndrome
RNA as Prognostic Biomarkers in Patients With Acute Coronary Syndrome
This study is trying to find specific RNA markers in the blood of people with acute coronary syndrome to see if they can predict heart problems after treatment.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 70 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | IRCCS Policlinico S. Donato Academic / other |
| Locations | 1 site (Milan, Milan) |
| Trial ID | NCT06058182 on ClinicalTrials.gov |
What this trial studies
This observational study aims to evaluate circulating RNA transcripts in patients with acute coronary syndrome (ACS) who are undergoing percutaneous coronary intervention (PCI). It focuses on identifying specific mRNAs and non-coding RNAs that may predict the risk of ventricular dysfunction following ACS. By analyzing whole genome transcriptomic data from blood samples, the study seeks to establish a signature of biomarkers that could indicate the likelihood of developing heart complications. The findings could enhance prognostic assessments and guide treatment decisions for ACS patients.
Who should consider this trial
Good fit: Ideal candidates include adults over 18 years experiencing their first episode of acute coronary syndrome and requiring PCI.
Not a fit: Patients with severe valve disease, previous cardiac surgeries, or those with contraindications to PCI will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved risk stratification and management of patients with acute coronary syndrome.
How similar studies have performed: While the approach of using RNA biomarkers is promising, the specific application in ACS and ventricular dysfunction is relatively novel and has not been extensively tested in prior studies.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Age \>18 years 2. Patients with ACS (first episode), defined according to the guidelines of the European Society of Cardiology (ESC) 2017 3. Indication for percutaneous revascularization treatment 4. Informed consent to study enrollment Exclusion Criteria: 1. Severe valve disease or other conditions requiring cardiac surgery 2. Previous cardiac surgery including coronary artery bypass grafts 3. Total chronic occlusions 4. Patients with known hypersensitivity or contraindication to any of the following drugs: * heparin * aspirin, * clopidogrel, * ticlopidine, * sirolimus, * everolimus. 5. Any contraindication to drug-eluting stent implantation (DES) 6. Patients with a documented history of myocardial infarction; 7. Left ventricular ejection fraction (LVEF) \<30% before PCI 8. Patients in cardiogenic shock 9. Patients with advanced ST-segment elevation myocardial infarction (\> 48 h from onset of symptoms/Q waves on electrocardiogram) or undergoing fibrinolysis; 10. Patients with prior known cardiomyopathy with LVEF \< 40% 11. Patients with malignant neoplasm or systemic disease with quoad vitam prognosis less than 1 year; 12. Patients with known active infectious diseases; 13. Patients who are unable to express valid informed consent to the act of enlistment 14. Pregnant women
Where this trial is running
Milan, Milan
- IRCCS Policlinico S. Donato, Milan, Italy — Milan, Milan, Italy (Recruiting)
Study contacts
- Study coordinator: Luca Testa
- Email: luca.testa@grupposandonato.it
- Phone: 0252774987
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.